Medtronic 2013 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2013 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 145

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145

75732me_10K.indd 10 6/25/13 6:39 PM
Table of Contents
Implantable Drug Infusion Systems. The SynchroMed II Implantable Infusion System delivers small quantities of drug directly
into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity
associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.
Deep Brain Stimulation (DBS) Systems. DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to
deliver mild electrical pulses to precisely targeted areas in the brain. DBS is currently approved in many countries around the
world for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease, refractory epilepsy (outside
the U.S.), severe, treatment-resistant obsessive-compulsive disorder (approved under an HDE in the U.S.), and chronic, intractable
primary dystonia (approved under an HDE in the U.S.). Our family of Activa Neurostimulators for DBS includes Activa SC (single-
channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable).
Gastroenterology & Urology Systems. Sacral neuromodulation uses a surgically implanted medical device, similar to a cardiac
pacemaker, called InterStim to help control the symptoms of overactive bladder, (non-obstructive) urinary retention, and chronic
fecal incontinence. The InterStim system consists of a thin wire lead and cardiac pacemaker-like device called a neurostimulator.
After a successful trial stimulation period, the system is implanted under the skin in the upper buttock and delivers mild electrical
pulses to stimulate the sacral nerves, which are involved in the control of bladder and bowel function. Enterra Therapy is the only
gastric electrical stimulation therapy approved in the U.S. (under an HDE), Europe, and Canada for use in the treatment of intractable
nausea and vomiting associated with gastroparesis. The system, which contains a small neurostimulator and two leads, stimulates
the smooth muscles of the lower stomach.
The charts below set forth net sales of our Neuromodulation products as a percentage of our total net sales for each of the last
three fiscal years:
10%
90%
Fiscal Year 2011
(dollars in millions)
Neuromodulation
$1,592
All Other
$13,916
11%
89%
Fiscal Year 2012
(dollars in millions)
All Other
$14,484
Neuromodulation
$1,700
11%
89%
Fiscal Year 2013
(dollars in millions)
All Other
$14,778
Neuromodulation
$1,812
Customers and Competitors
The primary medical specialists who use our pain management and movement disorder products are neurosurgeons, neurologists,
pain management specialists, anesthesiologists, physiatrists, and orthopedic spine surgeons. Our primary competitors in this
business are Boston Scientific and St. Jude.
The primary medical specialists who use our gastroenterology and urology products are urologists, urogynecologists,
gastroenterologists, and colorectal surgeons. Our primary competitors in this business are Allergan, Inc. and Urologix, Inc.
Diabetes
Our Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include
insulin pump therapy, continuous glucose monitoring (CGM) systems, and therapy management software.
The following are the principal products offered by our Diabetes business:
Integrated Diabetes Management Solutions. We have the only integrated insulin pump and CGM system in the U.S. Outside
the U.S., we offer our Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically
suspends insulin delivery when glucose levels become too low. The MiniMed Paradigm Veo System is labeled for use with Enlite,
our next-gen 6-day CGM sensor that is more accurate and more comfortable than our previous generation Sof-Sensor. In the U.S.,
we offer the MiniMed Paradigm Revel System, which incorporates new CGM features including predictive alerts that can give
early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events.
Professional CGM. In addition to Personal CGM (Enlite), we offer physicians a Professional CGM product called the iPro2/
iPro Professional CGM System. Physicians send patients home wearing the iPro2/iPro recorder to capture glucose data, which is
7